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ABSTRACT
Glioblastoma Multiforme (GBM) is a highly aggressive and devastating primary brain
tumour with a prognosis of 12-15 months with standard of care treatments, which
includes combinations of surgery, radiotherapy and chemotherapy. Aggressiveness,
among other factors, is driven by the populations of brain tumour initiating cells, capable
of self renewal, tumour recapitulation and high therapy resistance. Dinaciclib is a potent
cyclin-dependent kinase (CDK) inhibitor (CKI) which inhibits GBM cell growth in vitro.
This study confirmed the growth inhibition of GBM cells but also demonstrated
enrichment for specific brain tumour initiating cell populations upon dinaciclib treatment.
In the zebrafish (Danio rerio) model, dinaciclib showed less toxicity to the developing
embryos than NU2058, another CKI with similar CDK targets. Embryos injected with
U87 cells, a GBM cell line, were treated with dinaciclib and we demonstrated that there
was a decrease in cell foci area after treatment with dinaciclib compared to the vehicle
control. The breast cancer cells, MDA-MB-231, were also injected into zebrafish
embryos to perform a comparative analysis of spatial trends in cell metastasis.
Interestingly, there appears to be a preferential migration of injected cancer cells to the
organ of cancer origin, with GBM cells migrating towards the brain and head and breast
cancer cells migrating down the tail. In summary, we demonstrated that using a CKI
simultaneously with a chemotherapy induces antagonistic effects in GBM cells, which
demonstrates the importance of timing of drug administration in the clinic.
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INTRODUCTION
1.

Glioblastoma Multiforme

The most common primary brain tumours are gliomas, which originate from glial cells in
the brain (Seliger & Hau, 2018). The World Health Organization (WHO) has classified
gliomas from low (I-II) to high (III-IV) grade, based on aggressiveness and patient
prognosis, with the most aggressive cancer, Glioblastoma Multiforme (GBM), classified
as a grade IV glioma (Louis et al., 2016). GBM is very heterogeneous and demonstrates
high genomic instability, making the recurrent tumour more aggressive and resistant to
treatment. The average lifespan of GBM patients after diagnosis, under the standard of
care, is 12-15 months (Zimmer et al., 2019). GBM patients undergo a very aggressive
treatment regimen, beginning with maximal surgical resection, followed by radiotherapy
and chemotherapy (Jia, Wang, Yin, & Liu, 2019). Chemotherapy almost always consists
of temozolomide (TMZ), which may or may not be beneficial for patients, depending on
the methylation status of MGMT, a gene known to inhibit the function of TMZ. This
indicates a significant problem in current treatment options for GBM patients, as patients
are still being treated with TMZ achieving complete response at a rate of only 11%
(Gilbert et al., 2002).
2.

Main Obstacles in GBM Treatment.
2.1. Cancer Stem Cells/Brain Tumour Initiating Cells

Cancer stem cells (CSCs) play an essential role in therapy resistance and tumour relapse
in cancer (Brown et al., 2017). It is now known that CSCs represent a small
subpopulation of cells within tumours and have stemness characteristics such as capacity
to self-renew and generate differentiated cells that contribute to tumour heterogeneity
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(Kreso & Dick, 2014). The first evidence of CSCs was in acute myeloid leukemia
(AML), with the AML-initiating cells being identified based on the expression of a cell
surface marker, the cluster of differentiation 34 (CD34+), and the absence of the marker,
cluster of differentiation 38 (CD38-) (Lapidot et al., 1994). Different types of CSCs can
be isolated in the lab based on their cell surface marker expression status, which includes
CD44+/CD24- (breast cancer) (Al-Hajj, Wicha, Benito-Hernandez, Morrison, & Clarke,
2003), CD133+/CD24+/ESA+ (pancreas) (Li et al., 2007) and CD133+, CD44+ (glioma)
(Hemmati et al., 2003; Singh et al., 2004).
Glioma CSCs are also referred to as brain tumour initiating cells (BTICs) and
glioma stem cells (GSCs), and will be referred to as BTICs in this thesis. There is data to
support that BTICs cause therapy resistance and tumour recurrence (Brown et al., 2017;
Singh et al., 2004). They are often characterized by expression of proteins such as
CD133, CD44, SOX2, and OCT4, to name a few (Bradshaw et al., 2016; Brown et al.,
2017; Singh et al., 2004). CD44, a transmembrane glycoprotein involved in migration
and invasion, and angiogenesis, is used by BTICs and contributes to aggressiveness of
tumours (Senbanjo & Chellaiah, 2017). Spy1, also known as Speedy or RINGO, is a noncyclin cell cycle regulator protein which is also found to be highly expressed in GBM
(Ferby, Blazquez, Palmer, Eritja, & Nebreda, 1999; Lenormand, Dellinger, Knudsen,
Subramani, & Donoghue, 1999; Lubanska et al., 2014). Spy1 binds to and activates
cyclin-dependent kinase 2 (CDK2) independent of cyclin binding, allowing for a
premature G1/S phase transition in the cell cycle. Spy1 also promotes cell survival in
response to DNA damage caused by genotoxic agents (Barnes, Porter, Lenormand,
Dellinger, & Donoghue, 2003; Porter et al., 2002). Spy1 protein levels are upregulated in
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increasing stages of glioma, with grade III glioma and GBM having the highest levels.
Lubanska et al. showed that Spy1 advances the expansion of CD133+ BTIC populations,
possibly through the Numb/Notch pathway, making Spy1 a valid marker for BTIC
expansion (Lubanska et al., 2014).
Current chemotherapies largely target cancer cells based on their high
proliferation, affecting the rapidly dividing cells of the tumour. However, BTICs, like
CSCs found in other tissues, have a slower rate of division and thus mediate
chemoresistance and tumour recurrence following treatment (Baumann, Krause, & Hill,
2008; Eyler & Rich, 2008). There are other mechanisms contributing to the
chemoresistance of BTICs, which include the expression of ATP-binding cassette (ABC)
transporters. The ABC transporter proteins are a superfamily of membrane proteins
capable of converting energy from ATP hydrolysis to transport various substrates across
the cell membrane (Begicevic & Falasca, 2017). The ABC transporters C1 and B1 are
both highly expressed in BTICs and act to actively efflux many drugs, including TMZ,
etoposide, doxorubicin, and paclitaxel, among many others (Kolenda et al., 2011; Xi et
al., 2016). Hence ABC transporters contribute to the chemoresistance in BTICs that make
treating GBM particularly challenging. Another factor contributing to the drug resistance
in BTICs is the ability of these cells to activate the DNA damage response and repair
machinery (Maugeri-Sacca, Bartucci, & De Maria, 2012). BTICs can activate the ataxiatelangiectasia-mutated (ATM) serine/threonine kinase as well as the DNA damage
checkpoint kinases 1 (Chk1) and 2 (Chk2) in response to ionizing radiation, allowing the
BTICs to stall the cell cycle and repair DNA to avoid apoptosis (Bao et al., 2006). In
summary, BTICs contribute to the resistance of therapy and tumour relapse in GBM
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patients, and it is important to find drugs or treatment methods that target this population
of cells to improve the prognosis in GBM patients.
2.2. The Blood-Brain Barrier
A major issue in treating most central nervous system (CNS) diseases, including brain
cancers, is the ability to readily cross the blood-brain barrier (BBB). The BBB is a
semipermeable membrane that separates the brain from the circulating blood supply.
Consisting of different cell types such as cerebrovascular endothelial cells (CECs),
pericytes, astrocytes, and microglial cells, the BBB is a complex network of cells
providing an essential function to all vertebrates (Bundgaard & Abbott, 2008; Wang et
al., 2018). The CECs form tight junctions between cells and are usually the prominent
barrier in preventing molecules from crossing into the brain fluid (Wang et al., 2018).
The BBB allows for the passage of some molecules by passive diffusion, and other
critical molecules for proper neural function via selective transport, such as water, amino
acids, and glucose (Groothuis, 2000; Liebner, Czupalla, & Wolburg, 2011). The BBB is
an essential protective barrier to the most sensitive organ in the body; it is responsible for
limiting pathogens, solutes in blood, and large or hydrophilic molecules from entering the
cerebrospinal fluid (CSF). Although it does allow the diffusion of small hydrophobic
molecules such as O2 and CO2, as well as small polar molecules, such as acetaminophen,
the BBB is a major obstacle in the treatment of most CNS diseases, including brain
cancer, by limiting the access of therapeutic drugs to cross into the CSF (Johansen et al.,
2018; Stamatovic, Keep, & Andjelkovic, 2008). This also poses an obstacle in testing of
new drug targets at the clinical level and impairing any progress in therapy. There are two
major factors contributing to BBB penetration, the drug size must be lower than 400-500

4

Da, and the drug must form less than 8-10 hydrogen bonds with water (Cardoso, Brites,
& Brito, 2010; Pardridge, 2005). These criteria can be used as a general rule when
developing new drugs for treatment of diseases within the CNS, but a clinical trial will
verify the actual amount of drug that effectively crosses the BBB. Unfortunately, current
approach to drug development is focused on the target effect, and less effort is spent on
the delivery of the drug (Pardridge, 2009). One method to get around the BBB in the
treatment of GBM is through the use of a Gliadel® wafer. Carmustine, also known as
BCNU, is infused in the Gliadel® wafer, which is implanted under the skull in the space
left after the surgery to remove the GBM tumour. The wafer slowly dissolves, releasing
the drug into the space left after surgery (Xing, Shao, Qi, Yang, & Wang, 2015).
Although carmustine can readily cross the BBB, it has fewer toxic effects when used in a
wafer. This method allows for other large molecules to be applied directly to the former
tumour site. The Gliadel® wafer improves survival rates, but the drug delivery over time
is short and not ideal, as the majority of drug is released in the first week (Domb et al.,
1995; Shapira-Furman et al., 2019). The ideal wafer would release a consistent amount of
drug over a longer time period. This method illustrates one way to treat GBM without
having to consider the BBB. Another method of getting around the BBB is through the
use of pulsed ultrasound with injected microbubbles – microscopic bubbles of an
innocuous gas surrounded in a lipid coating – direct into the bloodstream. These
microbubbles will vibrate and disrupt the BBB when ultrasound is applied, and this
vibration disrupts the BBB and allows for drug passage that would not occur with an
intact BBB (Carpentier et al., 2016). Disruption of the BBB is a new and experimental
treatment method that requires more research and optimization.
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3.

The Cell Cycle and Cancer

The cell cycle consists of four separate phases, with checkpoints in-between and within
phases. The first growth phase, called Gap 1 phase (G1), is where cells gather enough
nutrients to duplicate their DNA. The second phase is S phase, or synthesis phase, where
DNA is synthesized. The third phase is the Gap 2 phase (G2), where more nutrients are
taken up and the cell prepares for the last phase, mitosis or M phase, where the cell
undergoes mitosis and divides into two daughter cells. Cells have the capacity to enter a
non-growth phase, G0, before it commits to replicating DNA. Most non-dividing, nongrowing cells in the human body, such as neurons and myocytes, are resting in the G0
phase (Norbury & Nurse, 1992). There are also four well characterized checkpoints in the
cell cycle, the first being located at the end of the G1 phase, which checks for DNA
damage, growth factors, and cell size. The next checkpoint is in the S phase, where there
is continual control of DNA quality as DNA is being replicated. There is a checkpoint at
the transition of the G2 to M phase, which is similar to the checkpoint at the end of the G1
phase, checking for DNA damage, sufficient nutrients and proper cell size to complete M
phase. The last checkpoint is during M phase at the beginning of anaphase, called the
spindle assembly checkpoint, which checks that chromosomes are aligned, and
centromeres are properly attached to the microtubules for equal distribution. The
checkpoints in the cell cycle are critical in maintaining healthy cells, by stopping the cell
cycle after damage, the cell can repair the damage or follow apoptosis and eliminate any
potentially harmful mutations (Kastan & Bartek, 2004).
The two major protein classes regulating the cell cycle are cyclins and CDKs.
There are as many as 29 different cyclins and 20 different CDKs in humans as of this
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writing, but the major cyclins involved in cell cycle regulation include cyclins A, B, D,
and E. Not all cyclins or CDKs are involved in cell cycle regulation, but the major CDKs
which are involved include CDKs 1, 2, 4, and 6 (Li, Qian, & Sun, 2019; Shen, Dean, Yu,
& Duan, 2019; Vermeulen, Van Bockstaele, & Berneman, 2003).
CDKs consist of a family of serine/threonine protein kinases, which are
constitutively expressed in cells, whereas specific cyclins are synthesized at specific
points in the cell cycle, hence their namesake. CDKs form a complex with cyclins, and
most CDKs have both activating and inhibitory phosphorylation sites that cause
conformational changes which may allow the complex to form and become activated
(Lim & Kaldis, 2013; Vermeulen, Van Bockstaele, & Berneman, 2003). These
complexes push the cell through the checkpoints in-between the phases in the cell cycle.
To be more specific, it is the binding of CDK4 and CDK6 to the group of cyclin D
(cyclin D1, cyclin D2, and cyclin D3), and the downstream phosphorylation events from
this complex, which are responsible for entry into the early G1 phase (Sherr, 1994).
Cyclin E-CDK2 complex is responsible for promoting the transition from G1 to S phase
(Ohtsubo, Theodoras, Schumacher, Roberts, & Pagano, 1995); CDK2 also binds with
cyclin A and this complex is required for transition through S phase (Girard, Strausfeld,
Fernandez, & Lamb, 1991; Walker & Maller, 1991). Cyclin A-CDK1 complex promotes
the cell into the M phase, and the cyclin B1-CDK1 complex is also responsible for
regulation in mitosis (Arellano & Moreno, 1997).
CDK activity is also regulated by another protein family, called CDK inhibitors
(CKIs), which consist of two major groups; the INK4 family, which bind to CDK 4/6
proteins, and the CIP/KIP family, which bind to both CDK and cyclin together in
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complex (Carnero & Hannon, 1998; Hengst & Reed, 1998). The INK4 proteins consist of
p15INK4b, p16INK4a, p18INK4c, and p19INK4d, which inhibit CDKs 4 and 6 by forming stable
complexes with CDK enzyme before binding with cyclin D, and thus block progression
of the cell cycle past the G1 checkpoint (Kim & Sharpless, 2006; Ortega, Malumbres, &
Barbacid, 2002). INK4 proteins are tumour suppressor proteins that play a role in
apoptosis, DNA repair, and senescence (Canepa et al., 2007; Roussel, 1999). The three
proteins of the CIP/KIP family include p21cip1/waf1, p27kip1, and p57kip2 (Harper et al.,
1995; Lee, Reynisdottir, & Massague, 1995; Polyak et al., 1994), and their main action is
inhibiting the G1/S and S phase CDKs (CDK1 and CDK2) (Sherr & Roberts, 1999).
Unlike the INK4 family, the CIP/KIP proteins have CDK independent roles in the cell,
which include the regulation of transcription, apoptosis, and the cytoskeleton (Besson,
Gurian-West, Schmidt, Hall, & Roberts, 2004; Coqueret, 2003; Wang, Elson, & Leder,
1997). The CIP/KIP family of proteins are responsible for inhibiting the cell cycle in the
G1 phase, inhibiting mostly the CDK2/4-cyclin complexes (Roskoski, 2019).
The cell cycle has many connections to the hallmarks of cancer (Hanahan &
Weinberg, 2011). Mutations causing the inactivation of CKIs such as in p16, p21, and
p27, remove the checkpoints in the cell cycle, allowing the cell to progress and divide.
This allows for uncontrolled cell growth and evasion of apoptosis, as well as genomic
instability, which contributes to tumour evolution (Hanahan & Weinberg, 2011; Williams
& Stoeber, 2012). The CDKs involved directly in regulating the cell cycle are
upregulated and often have increased activity in many cancers (Otto & Sicinski, 2017).
Inhibition of CDK2 in BTICs causes a downregulation of Sox2 levels, which is involved
in pluripotency (Liu et al., 2017). It is also common that GBM patients have
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amplifications of CDK 4 and 6, as well as deletions or inactivating mutations of
CDKN2A, which codes for p16 and p14, responsible for inhibiting CDK4 and CDK6
(Bronner et al., 2019). Other members of the CDK family are also involved in cancer,
which include CDK5, which promotes invasion and migration by down regulating the
actin regulatory protein caldesmon (Cheung & Ip, 2012; Quintavalle, Elia, Price,
Heynen-Genel, & Courtneidge, 2011), CDK8 has been identified as a coactivator of the
β-catenin pathway in colon cancer (Firestein et al., 2008), and CDK10 causes resistance
to endocrine therapy in breast cancer (Iorns et al., 2008).
4.

Common CNS Chemotherapies and Synthetic CKIs
4.1. Standard of Care and Other Chemotherapy

Currently the two most commonly used chemotherapy drugs for GBM treatment are
TMZ and carmustine (Minniti, Muni, Lanzetta, Marchetti, & Enrici, 2009; Rahman et al.,
2014). TMZ acts by alkylating/methylating DNA, at the N-7 or O-6 position of guanine
(Zhang, Stevens, & Bradshaw, 2012). This DNA damage signals the cell for apoptosis,
making it a useful chemotherapy. The action of TMZ can be counteracted by the DNA
repair gene MGMT, an enzyme capable of repairing the mutagenic lesion of O6methylguanine. The methylation status of the promoter of MGMT is a very powerful
prognostic marker in GBM. The methylated MGMT promoter results in the repression of
the MGMT protein, and therefore repression in DNA repair allowing for successful
action of TMZ (Wang et al., 2019). In 2004, a study by Hegi et al. showed that patients
with methylated MGMT promoter and treated with radiotherapy and TMZ had a median
survival of 21.7 months, compared to 15.3 months in patients treated with only
radiotherapy. In patients with an unmethylated MGMT promoter status, and thus an
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increased amount of the MGMT repair protein, the comparable survival rates were 12.7
and 11.8 months, respectively (Hegi et al., 2005). Unfortunately, the standard of care in
GBM treatment includes TMZ, regardless of MGMT methylation status.
TMZ or its derivatives can be delivered to a patient either intravenously or orally
and can be administered in combination with various treatment regimens. The current
standard treatment regimen is daily oral administration of 150-200 mg/m2 for 5 days over
a 28-day treatment cycle for 6 cycles following radiotherapy (Gilbert et al., 2013). TMZ
requires first-pass metabolism to be activated, making it a prodrug, which is a compound
that is pharmacologically activated after it has been administered and metabolized. At
physiological pH, TMZ is metabolized into 3-methyl-(triazen-1-yl) imidazole-4carboxamide (MTIC), which splits into two other metabolites responsible for methylating
DNA (Agarwala & Kirkwood, 2000). The second most used drug in GBM treatment is
carmustine, which is used in Gliadel® wafers inserted directly into the brain at the time
of surgery. Carmustine is an alkylating agent that can cause the formation of interstrand
crosslinks in DNA (Weiss & Issell, 1982; Woolley, Dion, Kohn, & Bono, 1976). Another
drug which is used to treat GBM, among other cancers, is Etoposide, a topoisomerase II
inhibitor (Tonder, Weller, Eisele, & Roth, 2014). It forms a stable complex with DNA
and topoisomerase II, which prevents re-ligation and leads to double strand breaks in the
DNA (Chen, Chan, & Hsieh, 2013; Wilstermann et al., 2007; Wu et al., 2011). This leads
to a stop largely at the G2/M checkpoint in the cell cycle (Higginbottom, Cummings,
Newland, & Allen, 2002; Nam, Doi, & Nakayama, 2010). These drugs represent the
conventional chemotherapy approach, non-specifically targeting rapidly growing cells
and leaving behind the CSCs, permitting tumour relapse.
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4.2. Synthetic CKIs
Natural CKIs are frequently mutated or deleted in cancer, allowing for unregulated cell
proliferation (Bailon-Moscoso, Cevallos-Solorzano, Romero-Benavides, & Orellana,
2017; Johansson & Persson, 2008; Sharma, Sharma, & Tyagi, 2008). Since the
downregulation of natural CKIs contributes to cancer progression, generation of synthetic
CKIs has the potential to aid in eradication of therapy resistant cancer cells. The first
synthetic CKI identified was flavopiridol in 1992, a pan-CDK inhibitor that inhibits
CDKs 1, 2, 4, 6 and 7 (Kaur et al., 1992; Sedlacek, 2001). Since then there have been
many synthetic CKIs developed and tested against cancer and a host of other diseases.
The first FDA approved CKI, palbociclib, an inhibitor of CDKs 4 and 6, was approved
for use in metastatic estrogen receptor positive breast cancer in combination with
letrozole in 2015 (Morikawa & Henry, 2015), and there are now two other FDA approved
CKIs as of this writing, abemaciclib and ribociclib (Kim, 2017; Mullard, 2017).
There are currently many clinical trials involving CKIs as single agent use or in
combination with other chemotherapies. One such CKI is dinaciclib, a potent second
generation CKI which targets CDKs 1, 2, 5, and 9 (Parry et al., 2010). Dinaciclib is
currently in phase I and II clinical trials with one completed phase III trial. One study
found dinaciclib, in combination with Bcl-2/Bcl-xL inhibitors, significantly reduced
GBM cell proliferation independent of p53 status (Jane et al., 2016). Dinaciclib binds to
the ATP site of CDK2 with an intricate network of hydrogen bonds and van der Waals
forces, which explains its high potency and selectivity for CDK2 (Martin, Olesen, Georg,
& Schonbrunn, 2013). Dinaciclib thus has great potential for treatment of GBM, as
several oncogenes cause synthetic lethality with CDK2 inhibition (Cheng et al., 2012;
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Lubanska & Porter, 2017; Molenaar et al., 2009). As a relatively new and understudied
drug, there is little known about dinaciclib, including any first pass effects or whether it
would be a good candidate drug used to cross the BBB. Clinical trials involving
dinaciclib have included cancers such as leukemia, melanoma, non-small-cell lung
cancer, and prostate cancer, but there are no trials involving GBM or any other brain
cancers (Nemunaitis et al., 2013; Rello-Varona et al., 2019). Due to its potency in vitro
and promising number of clinical trials for other types of cancer, it is of high importance
to test the effectiveness of this compound against BTICs.
O6-cyclohexylmethylguanine, referred to hereafter as NU2058, is an inhibitor of
CDK2 and CDK1, with Ki values of 12 ± 3 and 5 ± 1 µM, respectively. The Ki is defined
as the inhibitory constant and is reflective of the binding affinity of compounds. NU2058
binds to the ATP binding pocket of CDK2, in a distinct position which differs from other
purine-based inhibitors, such as roscovotine (Arris et al., 2000; Hardcastle et al., 2004;
Rigas, Robson, & Curtin, 2007). The pharmacology of CKIs such as first-pass
metabolism and half-life are lacking, and the field requires further research.
4.3. Drug Interactions and Bliss Independence Model
Drug interactions are an important aspect of every anti-cancer regimen due to their ability
to either diminish or enhance the action of an individual drug in the applied combination.
Drug interactions can be additive in effect, which is the expected result when the drugs
have no interactions; synergistic, the effect of interacting drugs is larger than the expected
additive result; and antagonistic, the reduced outcome from the expected additive results
(Greco, Bravo, & Parsons, 1995). The use of a drug as a monotherapy has its limits and
downfalls, as chemotherapies used alone typically only have one target, the efficacy is
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inadequate and the heterogenous tumour typically relapses from the resistant CSCs
(Spiro, Kovacs, & Csermely, 2008). Synergy between drugs is very important in treating
cancer. When two or more drugs are used, synergistic effects are desirable because of
increased efficacy and the decreased dosage used with the same or greater than expected
efficacy as opposed to the drugs used alone. The decreased dosage of synergistic drugs
causes fewer toxic effects seen in patients, and in general, drugs used in combination
delay the progress of drug resistance (Jia et al., 2009).
There are a few common methods used to calculate the drug interactions, which
include the Bliss independence model, Loewe additivity, and the Chou-Talalay method
(Bliss, 1939; Chou & Talalay, 1977; Loewe, 1928). These models are important in
determining which drugs can be used synergistically against cancer. These methods used
to calculate drug interactions address the same question but from different viewpoints.
Conceptually, the Bliss independence model emphasizes the treatment effect
enhancement, while the Loewe additivity model emphasizes on dose reduction, making
the Bliss independence model a more suitable model to study chemotherapy drug
combinations (Lotsch & Geisslinger, 2011; Zhao et al., 2014). The Bliss independence
model assumes no interaction between drugs and the combined drugs have different
mechanisms of action or target sites from each other (Foucquier & Guedj, 2015;
Pemovska, Bigenzahn, & Superti-Furga, 2018).
5.

Zebrafish as a High-Throughput in vivo Model

Animal models play an essential role in the development of novel anti-cancer drugs. Mice
have been established as the golden standard for model organisms when investigating
cancer biology under new therapy testing, which is due to the high genetic similarities
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between humans and mice, amongst many other reasons (Lampreht Tratar, Horvat, &
Cemazar, 2018). Despite multiple advantages of employing mice, mouse models are
relatively expensive and labour intensive, diminishing their utility in high-throughput
drug screening studies. Zebrafish (Danio rerio) have been established as an animal model
for developmental genetics in the 1960’s (Streisinger, Walker, Dower, Knauber, &
Singer, 1981). Approximately 70% of protein coding genes in zebrafish have their human
orthologs (Howe et al., 2013), and zebrafish do have similar physiology to humans,
which include organs such as heart, liver, and pancreas. These organs perform much of
the same functions as their human counterparts, such as the BBB, which is functionally
conserved in zebrafish and contain proteins responsible for tight junctions in the human
BBB, such as claudin-5 and ZO-1 (Fleming, Diekmann, & Goldsmith, 2013; O’Brown,
Pfau, & Gu, 2018). Another example is the cardiac electrophysiology, which in zebrafish
is more similar to humans than humans are to mice, with a comparable electrocardiogram
(ECG) between humans and zebrafish (Asnani & Peterson, 2014; Chi et al., 2008;
MacRae & Peterson, 2015). Additionally, cytochrome P450 is a family of enzymes
responsible for oxidation of endogenous and exogenous chemicals. In humans, these
enzymes are responsible for about 75% of drug metabolism. Zebrafish have a total of 94
cytochrome P450 genes, most of which are direct orthologs of human cytochrome P450
(Goldstone et al., 2010). A representative image of a zebrafish embryo aged 4 days post
fertilization (4dpf) and its anatomy are presented in Figure 1A.
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Figure 1: Anatomy and immune development of the zebrafish embryo.
(A) Image of a zebrafish embryo aged 4dpf with labelled anatomy. (B) Simplified
timeline of the immune system development in zebrafish. Note the adaptive immune
system (T- and B-cells) are not active until 2-4 weeks post fertilization. Image of
zebrafish embryo taken and provided by Janice Tubman.
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Furthermore, zebrafish have become an efficient tumour xenotransplantation
model first described by Lee et al. in 2005, who transplanted melanoma cells into the
blastodisc of very young (3.5 hours post fertilization) zebrafish embryos, promoting the
idea of zebrafish for tumour-based experiments (Lee, Seftor, Bonde, Cornell, & Hendrix,
2005). There are many advantages for the use of zebrafish as an animal model in tumour
xenotransplantation studies in comparison to mice. One advantage is the rapid embryonic
development, giving researchers eggs in less than 24 hours to work with. Compared to
mice with a gestation period of 21 days, zebrafish allow for faster experiments. Zebrafish
prefer to be housed in large groups, called shoals, and are much smaller requiring far less
maintenance than mice (Streisinger, Walker, Dower, Knauber, & Singer, 1981).
Zebrafish also produce many more spawn than mice, producing around 100-200 eggs per
breeding pair, compared to an average of 7-12 pups per litter in mice (Lampreht Tratar,
Horvat, & Cemazar, 2018; Mullins, Hammerschmidt, Haffter, & Nusslein-Volhard, 1994;
Streisinger, Walker, Dower, Knauber, & Singer, 1981). The development of the immune
system in zebrafish (Figure 1B) plays a critical role for the use of zebrafish in cancer
research. The adaptive immune system of the zebrafish is not fully active until fish are
around 21 days old, and there is an immature innate immune response starting at 24 hours
post fertilization (hpf). This allows for a primitive immune response against bacterium,
but injected cells are not detected by this innate immune system, allowing for tumour
transplantation at an early developmental stage without the need for genetically altered
immunocompromised organisms (Lam, Chua, Gong, Lam, & Sin, 2004; Lieschke &
Trede, 2009; Meijer & Spaink, 2011; Traver et al., 2003). Cells undergoing
transplantation are typically labelled with fluorescent dyes or are altered to constitutively
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express fluorescent protein in the cytoplasm, and then injected into the zebrafish,
commonly into the yolk sac of the developing embryo but can also be injected
orthotopically (the transplantation of specific tissue into its normal place in the body) and
as a xenograft in immunocompromised adult fish (Wertman, Veinotte, Dellaire, &
Berman, 2016). Because the embryos are transparent (Figure 1A), real-time live imaging
in zebrafish is relatively easy, and transparent adult zebrafish lines have been developed
allowing for live imaging at the single cell level, something not easily achieved in mice
(Ghotra et al., 2012; Spitsbergen, 2007; Stoletov, Montel, Lester, Gonias, & Klemke,
2007; White et al., 2008; Zhao, Tang, Cui, Ang, & Wong, 2009).
Recent work has suggested that zebrafish can be a great model for the
development of patient-personalized care, as patient-derived cells can be successfully
xenografted into adult immunocompromised fish and treated with different drug
combinations by orally gavaging fish (Yan et al., 2019). Zebrafish have been established
as a model organism for drug screening because they produce many progenies per
breeding pair, and there is enough fish that can be used to statistically evaluate the
outcomes. This is typically done in multi-well plates and embryos can be placed in
groups per well or individually in a single well. By performing drug screens this way,
many drugs, as well as many drug combinations, can be tested at the same time (Gibert,
Trengove, & Ward, 2013; MacRae & Peterson, 2015). All the advantages listed above
contribute to the cost effectiveness of zebrafish, adding yet another advantage of
zebrafish as an animal model for human cancer.
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6.

Hypothesis and Objectives

Hypothesis: Synthetic CKIs in combination with chemotherapy play an important role in
treatment of glioma cells and demonstrate characteristics advantageous for potential
combination therapy for patients with GBM.
Objectives: The first objective is to assess the effectiveness of a CKI and chemotherapy
as a combination therapy on GBM in vitro. The second objective is to characterize the
GBM cell populations post-treatment. Finally, the last objective is to assess the
effectiveness of dinaciclib in vivo using the zebrafish animal model.
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MATERIALS AND METHODS
1. Cell Culture
U-87 MG wild-type (WT) cells were obtained from ATCC and maintained in growth
media containing Eagle’s minimum essential medium (EMEM) (Quality Biological,
#112-018-101) supplemented with 10% fetal bovine serum (FBS) (Gibco, #10437028)
and 1% penicillin and streptomycin (Invitrogen, #15140148). Once cells reached 70-80%
confluency, plates were washed with serum-free EMEM and 700µL of 0.25% trypsin
(Hyclone, #SH3023601) was added and plate was incubated at 37°C for 3-5 minutes.
Cells were cultured at 37°C in 5% CO2 environment.
U-251 MG WT cells were a kind gift from Dr. Rutka (SickKids Hospital,
Toronto) maintained in EMEM growth media supplemented with 10% FBS, 1mM
sodium pyruvate, 1% non-essential amino acids, and 1% penicillin and streptomycin.
Once cells reached 80-90% confluency, plates were washed with serum-free EMEM and
700 µL of 0.25% trypsin was added and plate was incubated at 37°C for 5 minutes. Cells
were cultured at 37°C in 5% CO2 environment.
MDA-MB-231 (HTB26; ATCC) cells were cultured in Dulbecco’s Modified
Eagle’s Medium (DMEM; Sigma) supplemented with 10% FBS and 1% penicillin and
streptomycin and were maintained in an atmosphere of 5% CO2 at 37˚C.
2. MTT Assay and Bliss Independence Model
Cell viability was determined using an MTT (Thiazolyl Blue Tetrazolium Bromide)
assay. Cells were seeded in a 96-well plate at a density of 5x103 cells/well in a total of
100µL growth media, 24 hours before drug treatment began. The growth media was then
replaced with fresh growth medium containing different concentrations of each of the
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drugs TMZ (Selleckchem, #S1237), etoposide (Santa Cruz, #sc-3512), NU2058 (Santa
Cruz, #sc-202744A), and dinaciclib (Selleckchem, #S2768) every 24 hours for 3
consecutive days. After 24 hours of the last drug treatment, growth media was removed
and 100µL of a 50% mix of MTT solution (5mg/mL Thiazolyl Blue Tetrazolium
Bromide in filter sterilized PBS) (Sigma Aldrich, #M5655) and serum-free EMEM media
was added to the wells. The plate was then immediately incubated at 37°C for 3 hours,
then 150 µL of MTT solvent (4 mM HCl, 0.1% NP40 in isopropanol) was added to each
well and left on an orbital shaker for 15 minutes. Within one hour, plate was read on a
SpectraMax plate reader (Molecular Devices) for absorbance at OD=590 nm. The EC50
values were calculated using the free software Combenefit (Di Veroli et al., 2016). EC50
is defined as the half maximal effective concentration, and the quantal dose response
curve was calculated, which is the concentration of a compound where 50% of the
population exhibit a response.
The Bliss independence model was used for analysis of all combination drug
treatments. The Combenefit software (Di Veroli et al., 2016) was used to determine the
drug interactions using the Bliss model. The Bliss equation is as follows:
Yab,P = Ya + Yb - YaYb
Where Yab,P is the predicted percent inhibition, Ya is percent of inhibition from drug A at
dose a, and Yb is the percent of inhibition from drug B at dose b. Then the observed
percentage inhibition is calculated in the same way, denoted as Yab,O, which is then
compared to the Yab,P value. If Yab,O = Yab,P then there is an additive effect, if Yab,O >
Yab,P then there is a synergistic relationship of the two drugs in question, and if Yab,O <
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Yab,P then there is an antagonistic relationship of the two drugs in question (Zhao et al.,
2014).
3. Immunocytochemistry
Cells were grown on coverslips in 6-well plates at 37°C and 5% CO2. Growth medium
was aspirated off adherent cells and washed with warmed PBS twice. Cells were then
fixed with 1 mL of 4% paraformaldehyde (PFA) for 15 minutes, then 800 µL were
removed and 800 µL of PBS was added to each well. Plates were then wrapped in
parafilm and stored at -20°C until ready for continuation. Once ready, PFA/PBS mixture
was removed, cells were washed again with PBS, and coverslips were moved onto
labelled parafilm. Cells were washed 3 times with PBS-Triton Wash Buffer (0.05%
Triton X-100 in PBS) for 5 minutes each time. Cells were then blocked with blocking
buffer for 1 hour at room temperature. The primary antibodies CD44 (Novus, #NBP131488) (3.3:400), Ki67 (Abcam, #ab15580) (1:400), and CC-3 (cleaved caspase-3) (Cell
signalling, #9661S) (1:400) were prepared in 50% blocking buffer solution and 50%
PBS-Triton wash buffer, and 100 µL drops were placed on parafilm per coverslip.
Coverslips were placed cell side down onto primary antibody mixture and moved to a
humidity chamber and incubated at 37°C for 1.5 hours. Afterwards, coverslips were
moved onto parafilm at room temperature and washed 3 times with PBS-Triton wash
buffer with 50% blocking buffer for 5 minutes each wash. Secondary antibody mixture
was prepared in 50% blocking buffer in PBS-Triton wash buffer, and 100 µL drops were
placed on fresh parafilm, coverslips placed cell side down onto drops, and moved to a
humidity chamber at 37°C for 1 hour. Humidity chamber was covered with aluminum
foil for light sensitive secondary antibody. Coverslips were removed from humidity
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chamber and placed cell side up on parafilm at room temperature. Cells were then
washed for 5 minutes in PBS, followed by a 5-minute wash in Hanks Balanced Salt
Solution (HBSS). Then nuclear stain was done for 20 minutes at room temperature in
Hoechst (3 mL Hoechst in 5 mL HBSS) and covered in aluminum foil. Cells were then
washed with HBSS for 5 minutes, followed by PBS for 5 minutes, and then with distilled
water for 5 minutes. Coverslips were then mounted to slides and stored for imaging.
Images were taken using a Leica inverted microscope (Leica CTR 6500 microscope).
Images were quantified using ImageJ.
4. Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
RNA was extracted via Qiagen RNeasy Plus Mini Kit (Qiagen, #74136) as per
manufacturer’s instructions. Nanodrop lite Spectrophotometer (Thermofisher) was used
to calculate concentration and purity of RNA elution. Synthesis of cDNA was done via
qScriptTM cDNA SuperMix Master Mix (Quantabio, #95048) as per manufacturer’s
instructions. cDNA was stored at -20°C for short term storage and -80°C for long term
storage for future use. The qRT-PCR experiment utilized SYBR Green detection with
Fast SYBRTM Green Master Mix (ThermoFisher, #A25780), and reactions were run for
40 cycles in 10 µL total. Analysis was completed using Viia7 Real-Time PCR System
and software (Life Technologies). Samples were normalized to hGAPDH as an internal
control. The primers used were as follows:
hGAPDH forward

5’-GCACCGTCAAGGCTGAGAAC-3’

hGAPDH reverse

5’-GGATCTCGTCCTGGAAGATG-3’

hSpy1 forward

5’-TTGTGAGGAGGTTATGGCCATT-3’

hSpy1 reverse

5’-GCAGCTGAACTTCATCTCTGTTGTAG-3’

hMAP2 forward

5’-AGGCTGTAGCAGTCCTGAAAGG-3’
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hMAP2 reverse

5’-CTTCCTCCACTGTGACAGTCTG-3’

5. Animal Care and Toxicity Screen
WT zebrafish were handled in compliance with local animal care guidelines and standard
protocols of Canada and following the animal utilization protocol #19-03. Adult zebrafish
were kept at 28.5°C and bred according to “The Zebrafish Book” (Westerfield, 2000).
Eggs were collected and maintained in 28°C until 1dpf, where they were moved
to 33°C and subsequent embryos were placed into 12-well plates at 8 embryos per well
with E3 embryo media (5 mM NaCl, 0.17 mMKCl, 0.33 mM CaCl2, 0.33mM MgSO4,
10–5% Methylene Blue). Starting at 3dpf, E3 media was replaced with E3 media
containing either dinaciclib, NU2058, TMZ, or DMSO (dimethyl sulfoxide) at varying
concentrations. Embryos were fed once at 4dpf, before new drug treatments began, for 30
minutes until media was changed and drugs were added. Media was changed daily for 3
consecutive days, before drug treatments began, and dead embryos were counted and
removed each day. The sum of dead embryos was calculated 1 day after the last day of
treatment (6dpf) and percentage of dead embryos was calculated.
6. Zebrafish Injections
Cells for zebrafish injections were fluorescently stained up to 2 hours before injection.
Cells were washed with serum-free EMEM media and 0.25% trypsin was added for 5
minutes to allow adherent cells to detach from plate. A total of 5x105 cells were collected
and spun down at 1000 RPM for 5 minutes, media removed, and resuspended in 200 µL
of serum-free media. Then 5 µL of VybrantTM DiO (green) (Invitrogen) dye was added to
cell suspension and incubated at 37 °C for 20 minutes, with a quick and gentle vortex
every 5 minutes. Cells were spun down at 1000 RPM for 5 minutes at 4 °C, washed in
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serum-free EMEM media, centrifuged again as above, and cells were resuspended in a
final volume of 50 µL in serum-free EMEM media.
A 2% agarose gel was made in a 10 cm plate, and 0.168 mg/ml of Tricaine
(Sigma, MS222) solution was prepared. A prepared needle was already pulled, and the
day of injection was opened at the tip, placed into the Nanoject II microinjector
(Drummond Scientific) and oil was taken up. Oil was then released partially, and cells
were taken up into the needle. Embryos were anesthetized with tricaine before injection.
Embryos were placed onto agarose gel and roughly 10 nL of cell suspension was injected
into the yolk sac of embryos aged 2dpf. Successful injections were screened by imaging
all injected fish next day with a Leica inverted microscope (Leica fluorescence
stereomicroscope M205). Embryos were imaged at 35x magnification at the same
exposure and intensity. Successfully injected embryos were separated and maintained in
E3 media in 12-well plates at 8 embryos per well. Embryos were treated with dinaciclib
or DMSO in E3 media daily for 3 days. Embryos were maintained at 28°C until 1dpf, and
then moved to 33°C.
7. Zebrafish Imaging and Analysis
Embryos were imaged daily from 1 day post injection (1dpi) to 4dpi, and once at 7dpi.
Embryos were anesthetized in tricaine and placed onto 2% agarose gel for imaging. A
total of 4-5 embryos would be imaged at once, using a Leica fluorescent scope in the
GFP channel. Images were imported into ImageJ, converted to 8-bit greyscale, and
threshold was adjusted to eliminate background pixels. Threshold adjustments were kept
the same for all images of all days. Labelled cells were measured as foci area under total
area measured from raw integrated density. Results were moved to Excel, and total foci
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area was normalized starting at the last day of treatment (3dpi), so each treatment group
began with a normalized value of 1 on 3dpi.
8. Brain and Tail Metastasis Analysis
Images from 7dpi were used for analysis of metastases proximal to the brain. Foci were
considered to be proximal to the brain if they were above/past the swim bladder towards
the eyes, there was more than one foci away from the point of injection (yolk
sac/intestines), and there was at least one foci in the area of the brain according to Figure
1B (forebrain, midbrain, hindbrain). Foci were considered to be metastases down the tail
if they were past the swim bladder away from the eyes and there was more than one foci
away from the point of injection (yolk sac/intestines). Images from 3dpi embryos of
MDA-MB-231 injected cells were obtained from Janice Tubman. These images were
analyzed under the same conditions for both brain and tail metastases.
9. Statistical Analysis
GraphPad Prism 8.0.2 software was used for all statistical analysis except for matrix plots
of drug combinations. Drug combination and synergy evaluation significance was
completed using the Combenefit (Di Veroli et al., 2016) software, a one-sample Student’s
t-test was performed to test significance of drug interaction. A one-way ANOVA was
performed for number of nuclei, percent positive cells for antibodies Ki67, CD44, and
CC-3 from Figure 5 B and C, and a Tukey’s multiple comparison test was performed
from 5 different field of views (FOV) for each treatment. A one-way ANOVA was
performed on qRT-PCR data from Figure 5E with a Tukey’s multiple comparison test
from 3 separate experiments. Multiple t-tests using the Holm-Sidak method were
performed on foci area in embryos from Figure 7B from 2 groups per treatment with a 6-
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8 fish per group per treatment. A one-way ANOVA was performed on percentage of fish
with metastases proximal to the brain with a Tukey’s multiple comparison test from 2
groups with 6-15 fish per group per treatment. A two-way ANOVA was performed on
the comparison of metastases down the tail and proximal to the brain between the U87
cell line and MDA-MB-231 cell line from 2 groups per treatment, with 16-29 fish per
group.
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RESULTS
1. Selected CKIs and Chemotherapeutics Have an Antagonistic Relationship
Combination therapy consisting of two or more therapeutic agents is a widely used
approach in the clinic. To achieve the desired and successful treatment results, drugs are
combined to complete, fine-tune, and even enhance the action of one another. To
determine the potential synergistic relationship between CKIs and commonly used
chemotherapies, the EC50 was first determined for each drug. The GBM cell lines U87
and U251 were used to determine the drug interactions of four different drugs, which
include etoposide, TMZ, NU2058, and dinaciclib. EC50 values were determined using the
cell viability MTT assay. All values and corresponding growth curves were calculated
and produced using the free software, Combenefit (Di Veroli et al., 2016). Dinaciclib
showed the strongest negative effect on cell viability and had the most consistent EC50
values between the U87 and U251 cell lines at 11.2 nM and 13.7 nM, respectively
(Figure 2A).
Using Combenefit and the synergy and antagonism model, Bliss independence
model, matrix plots of synergy distribution and matrix plots along with the corresponding
surface plots of synergy distribution were developed for U87 cells (Figure 3) and U251
cells (Figure 4), respectively. The colour spectrum of the matrix plot presents antagonism
increase, red marking high levels of antagonism, yellow marking slight antagonism, and
green being an additive relationship. Alternatively, synergy increases as the colour
spectrum moves from green to blue, darker blue being very synergistic and light blue
being slightly synergistic. Values in the matrix plots represent the difference as a
percentage from the control, with the control being the expected additive value of two
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drugs, assuming there is no interaction between the two drugs. The results obtained for
the U87 cell line show there was slight antagonism for most concentrations used between
the drug combinations of NU2058 with etoposide and TMZ with dinaciclib (Figure 3).
There was a marked increase in antagonism in the drug combination of etoposide with
dinaciclib as dinaciclib concentration increased from 7.5 nM to 30 nM. The drug
combination of NU2058 with TMZ showed mostly an additive effect of the two drugs in
the different concentrations tested, however there was less significance within the matrix
plot at each concentration combination. Data obtained for U251 cell line showed that
every drug combination of a CKI with chemotherapy presented considerable antagonism
(Figure 4). The values determined for the concentrations resulting in a more additive
effect were found to be statistically not significant, unlike most antagonistic effects.
Overall, the selected CKIs and chemotherapeutics used in combination had an
antagonistic relationship in the U87 and U251 cell lines.
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Figure 2: EC50 values and inhibition curves of GBM cell lines.
GBM cell lines were treated with either dinaciclib, TMZ, etoposide, or NU2058 daily for
3 days, and cell viability was calculated via MTT assay. All EC50 values and graphs were
calculated with Combenefit software. (A) Represents U251 cell line and (B) represents
U87 (U87-MG) cell line. Interpolated EC50 values were calculated for TMZ and
etoposide in (B) due to low data points. All data points are given as a mean of 3 separate
experiments, error bars represent standard error of the mean.
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Figure 3: U87 matrix plots of synergy distribution from combination of a CKI and
chemotherapy.
Matrix plots of synergy distribution from different drug combinations in the U87 cell
line. Combinations included a CKI (dinaciclib or NU2058) and a chemotherapy (TMZ or
etoposide). Cells were treated daily for 3 consecutive days. Values in each box of the
matrix plot are given as an expected percentage difference from the additive effect of the
2 drugs combined, ranging from -100 (antagonism) to 100 (synergy). *p<0.05, **p<0.01.
Statistical significance was determined by Combenefit Software using a one-sample ttest.
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Figure 4: U251 surface plots and the corresponding matrix plots of synergy
distribution from combination of a CKI and chemotherapy.
Surface plots (left) and the corresponding matrix plots (right) of drug combinations used
for U251 cell line. Cells were treated for 3 consecutive days. Values in each box of the
matrix plot are given as an expected percentage difference from the additive effect of the
2 drugs combined, ranging from -100 (antagonism) to 100 (synergy). *p<0.05. Statistical
significance was determined by Combenefit Software using a one-sample t-test.
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2. Dinaciclib Selects for a Stem-like Population of GBM Cells
To analyze the post-treatment GBM cell populations, immunocytochemistry was
performed utilizing U251 cells treated with dinaciclib, TMZ, or a combination of both.
Cells were treated with 15 nM dinaciclib, or 50 µM TMZ, or a combination of both
drugs. These values were slightly higher than the calculated EC50 values for U251 cells
(11.2 nM for dinaciclib, 38.5 µM for TMZ). Cells were stained with antibodies for the
proliferation marker Ki67, the stem-cell marker CD44, the apoptosis marker CC-3, and
DAPI for nuclear staining. Slides were imaged (Figure 5A) and 5 images per slide were
taken at the magnification of 20x and analyzed using ImageJ. Dinaciclib significantly
decreased total number of nuclei per FOV, both as a single agent and in combination with
TMZ, compared to the control, treated with an equivalent amount of DMSO, as well as to
TMZ alone (Figure 5B). Next, the staining was quantified to determine the percent of
positive cells for each antibody (Figure 5C). Dinaciclib significantly increased the
number of cells positive for the proliferation marker Ki67 in the remaining post-treatment
cell population, compared to control, and when used in combination with TMZ the
proliferation marker was also significantly increased compared to the control and TMZ
alone. A similar effect was observed for the stem cell marker CD44 expression.
Dinaciclib significantly increased the amount of CD44+ cells when used alone or in
combination with TMZ compared to both TMZ alone and the control. There was a
significant increase of roughly 20% of cells positively staining for CC-3 observed in the
dinaciclib/TMZ combination treatment compared to control. Analysis of the GBM posttreatment populations suggests that dinaciclib is selecting for a more stem-like
population.
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To further characterize and confirm the stemness of the remaining population
after dinaciclib and TMZ combination treatment, cells were treated with vehicle control,
dinaciclib, TMZ, or the combination of both at the same concentrations and conditions as
above. Cells were collected and a qRT-PCR was conducted (Figure 5D). Results are
given as log10 RQ (relative quantity) in comparison to the control. Dinaciclib and the
combination of dinaciclib and TMZ caused significant increases in the GBM cell clonal
expansion marker, SPDYA, coding for Spy1 protein, compared to TMZ treatment alone.
MAP2 is a commonly used differentiation marker, responsible in cytoskeleton regulation
in brain nerve cells. There is lower expression of MAP2 in gliomas compared to normal
brain tissue (Zhou et al., 2015). There was also a significant decrease in MAP2 transcript
levels of the combination treatment of dinaciclib and TMZ when compared to TMZ
alone. Dinaciclib also caused a decrease in MAP2 transcript levels when compared to the
control group and TMZ alone, although these results are not statistically significant
(Figure 5E). In summary, dinaciclib inhibits growth of GBM cells and selects for a more
stem-like population.
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Figure 5: Dinaciclib decreases cell numbers and induces apoptosis in combination
with TMZ.
(A) Representative images from immunocytochemistry of U251 cells stained with DAPI
and antibodies for CD44, Ki67, and CC-3. Cells were treated with either 50 µM of
DMSO as vehicle control (CONTROL), 50 µM of TMZ, 15 nM of dinaciclib (DINA) or
a combination of both (50 µM TMZ + 15 nM DINA). Images were taken at 100x oil and
scale bars represent 40 µm. (B) Total number of nuclei from each group was quantified
using images taken at 20x and ImageJ. Error bars represent standard error of the mean
from 5 different images taken. ***p<0.001. Statistical significance calculated using a
one-way ANOVA. (C) Percentage of cells positively stained for each antibody of Ki67,
CD44, and CC-3. Total number of cells were counted using the same method as (B) and
cells stained for each antibody was counted in the same method under Texas red filter
image. Error bars represent standard error from 5 collected data points from 5 separate
images. *p<0.05, **p<0.005, ***p<0.001. Statistical significance was calculated using a
one-way ANOVA. (D) Schematic of CD44+ cells being isolated from dinaciclib
treatment and mRNA levels tested with qRT-PCR. Image created with biorender.com.
(E) Log10 Relative Quantity (RQ) of SPDYA and MAP2 mRNA levels in U251 cells.
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3. Total Foci are Reduced in vivo with Dinaciclib Treatment
A schematic of the workflow for zebrafish injections is presented in Figure 6. Drugs
tested in zebrafish embryos are shown in Table 1, and dinaciclib demonstrated the lowest
amount of lethality and was therefore selected to be used. U87 cells were fluorescently
labelled and injected into anesthetized embryos. Successfully injected embryos were
treated with a high and a low concentration of dinaciclib, 75 nM and 7.5 nM,
respectively. Images were taken daily of all embryos up until 7dpi (Figure 7A). Total foci
area was measured using the raw integrated intensity from ImageJ analysis. Each group
was then normalized to itself starting at 3dpi, the time when drug treatment ended. At
4dpi there was a significant decrease of the foci area when the high concentration of
dinaciclib was used, compared to the low concentration, but the decrease was not
significant when compared to the DMSO treated control fish. However, at 7dpi, there was
a significant decrease in foci area in the high concentration of dinaciclib compared to
both the control and the low concentration of dinaciclib (Figure 7B). In summary, it was
found that dinaciclib was less toxic to embryos and caused a decrease in total foci in vivo
compared to the vehicle control.
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Figure 6: Schematic of zebrafish injections.
(A) GBM cells were labelled with fluorescent dye and injected into anesthetized
zebrafish embryos 2 days old. (B) Fish were placed in a 12-well plate at 8 fish per well.
Fish were imaged and screened 24 hours after injection to select successfully injected fish
to be subsequently moved to a new plate. (C) Drug treatments and vehicle control were
added 24 hours after injection. (D) Images were taken using an inverted microscope
(Leica) every day before each treatment. Image created with biorender.com
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Table 1: Drug viability in zebrafish embryos
Treatment
Concentration
dinaciclib§
25 nM
250 nM
1000 nM
Total Embryos
50
50
50
Embryos Alive
50
49
50
% Death
0
2
0
*
*
*
DMSO Vehicle Control
Total Embryos
50
50
50
Embryos Alive
49
49
48
% Death
2
2
4
—————————————————————————————————————
NU2058§
25 µM
50 µM
100 µM
Total Embryos
55
54
56
Embryos Alive
35
33
2
% Death
36.36
38.89
92.86
*
*
*
DMSO Vehicle Control
Total Embryos
54
55
55
Embryos Alive
51
54
53
% Death
5.55
1.82
3.63
—————————————————————————————————————
TMZ†
40 µM
125 µM
250 µM
Total Embryos
30
30
30
Embryos Alive
30
29
30
% Death
0
3.33
0
*
*
*
DMSO Vehicle Control
Total Embryos
N/A
N/A
30
Embryos Alive
N/A
N/A
27
% Death
N/A
N/A
10
* DMSO vehicle control was matched in dilution to media to corresponding drug
treatment
§ Result of 2 separate experiments
† Only one replicate completed, vehicle control only done at one concentration
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Figure 7: Dinaciclib reduces relative tumour area.
(A) Representative fluorescent and overlay images of zebrafish used for analysis.
Embryos were anesthetized with Tricaine and injected with U87 cells. Scale bars equal
500 µm. Top image represents a sham injected embryo. (B) Tumour area was measured
at 3, 4, and 7dpi. Tumour area was normalized to 3dpi, the day treatments ended.
Intensity of foci was measured using ImageJ. Error bars represent the standard error from
2 groups, each group representing at least 6 fish. *p<0.05. Statistical significance was
calculated using multiple Student’s t-tests.
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4. Dinaciclib Reduces Metastases Proximal to the Brain
Images taken at 7dpi were also analyzed for metastases proximal to the brain. Fish that
had foci past the swim bladder, towards the eyes and away from the point of injection
(yolk sac/intestines) and appeared to be near the brain (see Figure 1A) were quantified as
fish with metastases proximal to brain. Figure 8A shows representative images from the
DMSO vehicle control group with foci of U87 cells which were declared as fish with
metastases proximal to the brain (red arrows). Each treatment group was measured this
way and then total fish with metastases proximal to the brain were put into a percentage
of the total amount of fish in that treatment group. Although there was no significance
between groups, there is a trend of decreased metastasis towards the brain as dinaciclib
concentration increases (Figure 8B). Images from the DMSO control group and no
treatment (NT) group were then analyzed for total brain metastases and total tail
metastases and then compared to untreated 3dpi embryos injected with breast cancer cells
(MDA-MB-231). Tail metastases were measured by foci detected past the swim bladder
(see Figure 1A). There were significantly more metastases proximal to the brain in fish
injected with the U87 cell line, and a significant increase in tail metastases in fish injected
with the MDA-MB-231 cell line (Figure 8C). Representative fluorescent and overlay
image of a fish injected with U87 cells with tail metastases can be seen in Figure 8D.
Although more work is needed as validation, it would appear the U87 cell line
preferentially migrates towards the brain, and dinaciclib reduces this metastasis in vivo.
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Figure 8: Dinaciclib reduces metastasis towards the brain.
(A) Representative fluorescent and overlay images of 7dpi zebrafish. U87 foci (red
arrows) show metastasis in the vicinity of the midbrain and hindbrain. Both images are
from the DMSO vehicle control group. Scale bars equals 500 µm. (B) Images were
analyzed and put into categories of no metastases proximal to brain and metastases
proximal to brain. There was no significance between groups according to a one-way
ANOVA. NT = no treatment, DMSO = vehicle control, DINA = dinaciclib. Error bars
represent the standard error from 2 groups, each group representing at least 6 fish. (C) All
7dpi fish from NT and DMSO groups were analyzed for brain and tail metastases, and
additional images of the breast cancer cell line MDA-MB-231 cells injected into the yolk
sac were obtained from Janice Tubman and analyzed for brain and tail metastases.
Images analyzed from Janice Tubman were taken at 3dpi. Error bars represent the
standard of error from 2 groups, each group containing at least 16 fish. *p<0.05,
**p<0.005. Statistical significance was calculated using a 2-way ANOVA. (D)
Representative fluorescent and overlay images of 7dpi zebrafish injected with U87 cells.
U87 foci (red arrowheads) show metastasis down the tail. Both images are from the
DMSO vehicle control group. Scale bars equals 500 µm.
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DISCUSSION
Since the introduction of TMZ over a decade ago, the standard of care for patients with
GBM has not been challenged to advance the clinical outcomes leaving patient survival
rates in the same dismal position (Cantrell et al., 2019). It is therefore important to
continue to explore new treatment and therapy options, including novel drugs and drug
combinations, to improve survival rates and quality of life for patients with GBM.
This study aimed to validate different combinations of CKIs and chemotherapy in
the treatment of GBM in vitro. We found that all combinations of a CKI and
chemotherapy tested caused high antagonism between the two drugs at most of the
concentrations used in U251 cell line (Figure 4). The U87 cell line showed similar
results, and although the combination of TMZ and NU2058 showed an overall additive
effect, only 2 of the 9 matrix plots were tested significant, compared to 5 to 7 of 9
significant matrix plots of all other matrix plots for U87 cell line (Figure 3). Additionally,
there were two EC50 values (TMZ and etoposide) that were determined through
interpolation in the U87 cell line. We recognize that these drugs barely cause 50%
inhibition in the U87 cell line, and this demonstrates the high chemoresistance of GBM.
This emphasizes the need for synergistic drug interactions in GBM treatment, especially
because these interpolated results come from the currently used chemotherapies and not
from the experimental CKIs. The observed antagonistic relationship could potentially
result from the counteractive mechanisms of action of the drugs tested. The CKIs work
by inhibiting CDKs and subsequently the cell cycle, stopping cells from dividing and
growing (Hardcastle et al., 2004; Parry et al., 2010; Sedlacek, 2001). However, typical
chemotherapy agents work by targeting actively dividing cells, causing DNA damage
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either directly or indirectly, leading to apoptosis (Chen, Chan, & Hsieh, 2013;
Wilstermann et al., 2007; Wu et al., 2011; Zhang, Stevens, & Bradshaw, 2012). The
timing of drug administration could be a major factor for the antagonism between a CKI
and chemotherapy agent and should be further investigated. Recent work including
bevacizumab, an angiogenesis inhibitor, addresses the issue of treatment timing in GBM
patients in the clinic. Pasqualetti et al. showed that the timing of bevacizumab
administration affected the median time of disease recurrence from the initial GBM
diagnosis, from 9.9 months for early bevacizumab administration (after first line
chemotherapy) to 13.1 months for delayed bevacizumab administration (after second- or
third-line chemotherapy) (Pasqualetti et al., 2018). Although the overall survival rates
were unchanged, this study shows that timing of bevacizumab administration may at least
play a role in improving the quality of life for GBM patients.
In terms of CKI and chemotherapy treatment, the timing could be critical
depending on the specific characteristics of the combined drugs. For example, if a
chemotherapy agent causes DNA damage at the end of G1 checkpoint or at mid S phase
checkpoint, and a CKI causes a cell cycle stop at the G2/M checkpoint, it may be more
beneficial to treat with the chemotherapy agent first. This would allow for DNA damage
to accumulate, for the subsequently applied CKI, to stop the cell cycle at the end of DNA
accumulation, allowing for more time to detect DNA damage and for activation of
appropriate molecular signals toward apoptosis. Alternatively, if the chemotherapy agent
causes DNA damage late in the cell cycle, it may be more beneficial to first treat with a
CKI, which stops the cell cycle early, allowing the cells to synchronize, followed by
treating with the chemotherapy after the CKI has been metabolized. This approach may
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result in optimizing the number of cells affected by the chemotherapy, increasing the
cytotoxic effects and reducing chemoresistance.
Jane et al. showed that dinaciclib, in combination with Bcl-2/Bcl-xL inhibitors,
significantly reduced GBM cell proliferation rates independent of p53 status, and there
was little to no effect on cell population or apoptosis in the GBM cell line T98G when
dinaciclib was combined with other chemotherapeutics, including TMZ and etoposide.
However, a very high concentration of dinaciclib was used, at 1 µM, which is as much as
1000 times higher than the calculated IC50 values for the inhibition of CDK2 and CDK5
(1 nM). In addition, cells were only treated for 24 hours, limiting the time for cells to
accumulate DNA damage and signal for apoptosis (Jane et al., 2016). These high
concentrations of dinaciclib could be a factor in the results seen in combination
treatments with other chemotherapeutics. It has been demonstrated recently that
dinaciclib in low concentrations (5 nM), in combination with doxorubicin, enhanced
senescence in the multiple myeloma cell line RPMI-8226 (Tang, Xu, Liang, & Gao,
2018). The data presented by Jane et al. is consistent with this work; dinaciclib alone
causes growth inhibition, but not cell death, in GBM cells. Our data show that cultures
treated with dinaciclib alone and in combination with TMZ significantly reduced the total
number of cells (Figure 5B). Furthermore, our study is the first to characterize the postdinaciclib treatment cell populations. The remaining cells demonstrate more stem-like
and aggressive character with elevated protein expression of stem-cell marker CD44 and
proliferation marker Ki67, as well as increased transcript levels of BTIC expansion
marker SPDYA and decreased transcript levels of the differentiation marker MAP2. These
results suggest that dinaciclib selects for and leaves behind aggressive and drug resistant
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cell populations. This particular outcome of dinaciclib treatment could potentially serve
as an important strategy for combination therapy as it selects BTIC population to be
specifically targeted by another agent, limiting the expansion of the cells at the same
time. Further work is needed, however, to determine the role of administration timing as
well as potential agents to cooperate with the BTIC selective nature of dinaciclib. In
summary, our and published data show that other parameters such as timing and
mechanism of action along with drug concentration, play a pivotal role in the anticancer
action of combined agents and should be carefully investigated while designing treatment
regimens.
To address the effects of combination therapy in vivo, we utilized zebrafish
xenograft and drug testing model. Despite several advantages of utilizing zebrafish there
are many controversies about the model for cancer research. One large disadvantage in
tumour transplantation using zebrafish is the temperature difference. Zebrafish embryos
are maintained at 28°C, a large gap from the human body at 37°C. Most researchers
compromise proper development of the embryo and optimal growth temperatures of the
tumour cells, by exposing both embryos and xenografted cells to an “in-between”
temperature, ranging from 32.5-35°C (Barriuso, Nagaraju, & Hurlstone, 2015; CabezasSainz et al., 2018; Kirchberger, Sturtzel, Pascoal, & Distel, 2017). A recent study by
Cabezas-Sainz et al. suggests that injection and maintenance at 36°C optimizes cell
growth and has no significant effect on the development of the embryo when compared to
34°C (Cabezas-Sainz et al., 2018). Yan et al. also showed a transgenic zebrafish model
that could maintain normal function at 37°C and could be xenografted with a large
number of different human cancers (Yan et al., 2019). In this study, embryos were kept at
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28°C upon collection for 1 day, where they were subsequently moved to 33°C for the
remainder of the experiments.
Additionally, zebrafish are not an ideal model for human diseases that take place
in specific organs of the human body that zebrafish do not have, including prostate,
breast, and lungs (Kirchberger, Sturtzel, Pascoal, & Distel, 2017). Despite those
limitations, zebrafish offers cancer studies in a high-throughput manner, where human
cells can be readily xenografted at certain immunocompromised stages of zebrafish
development into an in vivo microenvironment (Greaves & Maley, 2012; Wertman,
Veinotte, Dellaire, & Berman, 2016). Standard drug treatment of zebrafish embryos
involves adding the drug to the water the embryos are in, which results in drugs taken up
passively through the skin of the embryos (Kari, Rodeck, & Dicker, 2007). It is possible
to measure the amount of drug absorbed by the zebrafish embryos using liquid
chromatography-tandem mass spectrometry (Chen et al., 2017; Zhang, Qin, Zhang, &
Hu, 2015). However, there is currently no way to measure the exact amount of drug being
metabolized by zebrafish embryos.
Figure 6 is a graphical abstract of the method used in this thesis to inject and
collect data from the zebrafish embryos. This method involved using groups of embryos
in a larger well and analyzing the averages of the groups. It is not uncommon that other
researchers look at each fish individually, and each method has its own advantages and
disadvantages. When looking at each fish individually, each fish is placed in a single well
of a 96-well plate creating a high-throughput study platform (Basnet, Zizioli, Taweedet,
Finazzi, & Memo, 2019; Ferraiuolo, Tubman, Sinha, Hamm, & Porter, 2017; Lambert et
al., 2018). Although technically advantageous, this adds multiple layers of stress on the
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embryo, which includes the small size of the well and feeding the fish in small confined
space causing increased ammonia levels and an increased pH. In a smaller space these
toxicities would theoretically accumulate faster due to the smaller volume of water. A
major concern at this point is supplying the nutrition to the embryo but keeping them
under consistent and not compromised environment during drug treatment. It is well
established that the yolk is fully diminished by ~7dpf, and it is essential that the embryos
are fed from this point on, but ideally 1-2 days before (Mathias, Saxena, & Mumm,
2012). The time required for establishing tumour foci and tumour mass significantly
exceeds that range of time, making it essential to keep the embryos fed. Using a 96-well
plate to study zebrafish embryos individually is much more beneficial when comparing
each fish individually over time during toxicity screens and for live imaging at the single
cell level (White et al., 2008). When using zebrafish embryos for drug screening one can
make the case for a larger well and pooling groups of embryos and averaging the results.
By using a less stressful environment the embryos are healthier and subjected to more
consistent environment with less possibility for an error.
The potential toxic effects of two CKIs, dinaciclib and NU2058, were tested on
zebrafish embryos. Dinaciclib was non-toxic in the embryos at concentrations as high as
89-fold higher than the calculated EC50 values in the GBM cell lines used.
Comparatively, NU2058 was extremely toxic to the embryos at concentrations close to
the EC50 values, making it a poor drug to move forward with drug screening using
zebrafish embryos (Table 1). NU2058 is an experimental drug not seen in recent
literature, suggesting that the toxicity of this drug to animal models quickly eliminated it
from use in research. On the other hand, dinaciclib is still being used today in clinical
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trials. When zebrafish embryos were injected with U87 cells and subsequently treated
with dinaciclib, there was a significant decrease in foci area in high concentration (75
nM) compared to vehicle control (DMSO) or low concentration (7.5 nM) after 4 days
from the last treatment (Figure 7B). This would suggest that dinaciclib had successfully
caused growth inhibition of injected U87 cells in the embryos, which is consistent with
what is seen in vitro. The same embryo images were used in analysis of metastases of
U87 cells (Figure 8). Although there were no significant differences seen (Figure 8B),
there is a trend demonstrating that dinaciclib is reducing the total number of metastases
towards the head. The limitations of this data are due to low replicate numbers (n=2), and
future work would include the addition of more replicates as well as the addition of more
GBM cell lines as well as patient-derived cell lines. Of the fish injected with U87 cells,
the DMSO vehicle control and no treatment groups had a high percentage of fish with
metastases proximal to the brain, but when analyzed for tail metastases, there were very
few. Images of 3dpi embryos, injected with MDA-MB-231 cells (a breast cancer cell
line), were obtained from Janice Tubman and analyzed the same way as the U87 cell
injected embryos for brain and tail metastases. Interestingly there were no metastases
proximal to the brain, but many down the tail (Figure 8C). This data would suggest that
the human GBM cells are preferentially migrating towards the brain, confirming the
validity of zebrafish as an animal model. The human MDA-MB-231 cells are a known
invasive cell line, and there is evidence of those cells metastasizing throughout the
zebrafish embryo once injected, including to the brain, eye, and tail, but no data on the
amount of fish with specific metastases (Tulotta et al., 2016). There is also evidence of
those cells metastasizing to the bone in zebrafish embryos (Mercatali et al., 2016). As
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high as 70% of breast and prostate cancer patients with relapse develop bone metastases
(Ibrahim, Mercatali, & Amadori, 2013; Mercatali et al., 2016; Roodman, 2004), and, as
mentioned above, zebrafish lack specific organs that humans have, such as prostate,
breast, and lungs (Kirchberger, Sturtzel, Pascoal, & Distel, 2017). The fact that the breast
cancer cell line MDA-MB-231 tends to metastasize down the tail is interesting, and the
lack of breasts within the zebrafish is of further interest. Future work would be needed to
test this, for example, injecting zebrafish embryos with different types of human cancers,
some with common organs (brain and liver), and some without (breast and prostate), and
quantifying the amount of metastasis and localization of that metastasis. This experiment
could solidify the use of zebrafish as an animal model for cancer, and potentially put
some controversies to rest. This experiment would require sectioning and staining of
zebrafish in order to confirm the localization of the transplanted cells. This highlights
more future work required for this thesis, sectioning and staining injected zebrafish
embryos to determine if the U87 cell line had in fact metastasized to the nervous tissue.
In conclusion, this thesis has demonstrated that dinaciclib, in concurrent
combination with a chemotherapy, is antagonistic in the GBM cell lines U87 and U251,
and dinaciclib inhibits GBM cell growth and selects for the BTIC population in vitro.
This advocates the potential use of dinaciclib in treatment of GBM, in combination with a
treatment targeting the CD44+ BTIC population, and also addresses the question of the
timing of drug treatments in the clinic, especially in clinical trials involving CKIs.
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